Courier Capital’s aTyr Pharma ATYR Stock Holding History

Courier Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$18K	–	402
2025 Q3	$18K	Buy	+25,000	New	+$113K	﹤0.01%	390

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Courier Capital's ATYR Position: Q4 2025 in Review

Courier Capital sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 25,000 shares — an estimated $18K sold.

Courier Capital first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $18K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

Courier Capital reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
Courier Capital sold 25,000 aTyr Pharma shares in Q4 2025, an estimated $18K.
Courier Capital first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
Courier Capital's aTyr Pharma position peaked at $18K in Q3 2025.
84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Courier Capital's 13F filing for Q4 2025, filed 29 Jan 2026.